Zimmer Biomet (NYSE:ZBH) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Zimmer Biomet (NYSE:ZBH) from a hold rating to a buy rating in a research note published on Saturday,Wall Street Zen reports.

A number of other equities research analysts also recently commented on ZBH. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research report on Wednesday, August 5th. Canaccord Genuity Group lifted their price objective on Zimmer Biomet from $83.00 to $100.00 and gave the stock a “hold” rating in a report on Monday, August 10th. Robert W. Baird set a $104.00 price objective on Zimmer Biomet in a research report on Thursday, August 6th. UBS Group reissued a “buy” rating and issued a $120.00 target price on shares of Zimmer Biomet in a report on Thursday, August 6th. Finally, Barclays raised Zimmer Biomet to a “hold” rating in a research report on Wednesday, October 7th. Seven analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $104.47.

Zimmer Biomet Price Performance

ZBH opened at $97.27 on Friday. The company’s 50-day simple moving average is $94.79 and its two-hundred day simple moving average is $91.74. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. The stock has a market capitalization of $18.55 billion, a P/E ratio of 11.37, a P/E/G ratio of 2.32 and a beta of 0.49. Zimmer Biomet has a 52-week low of $79.12 and a 52-week high of $103.70.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating the consensus estimate of $2.01 by $0.06. The firm had revenue of $2.18 billion during the quarter, compared to analysts’ expectations of $2.13 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The firm’s quarterly revenue was up 4.8% on a year-over-year basis. During the same period in the previous year, the company earned $2.07 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, analysts predict that Zimmer Biomet will post 8.54 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th were given a $0.24 dividend. The ex-dividend date was Wednesday, September 30th. This represents a $0.96 annualized dividend and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.36%.

Insider Buying and Selling at Zimmer Biomet

In other news, insider Chad F. Phipps sold 3,000 shares of the company’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $98.35, for a total value of $295,050.00. Following the completion of the sale, the insider directly owned 65,231 shares in the company, valued at $6,415,468.85. This represents a 4.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Kevin R. Thornal sold 5,691 shares of the company’s stock in a transaction on Friday, September 11th. The stock was sold at an average price of $92.95, for a total value of $528,978.45. The SEC filing for this sale provides additional information. Company insiders own 1.28% of the company’s stock.

Hedge Funds Weigh In On Zimmer Biomet

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Asset One Wealth Management LLC bought a new position in shares of Zimmer Biomet in the third quarter worth about $204,000. Calamos Advisors LLC lifted its holdings in Zimmer Biomet by 2.1% during the third quarter. Calamos Advisors LLC now owns 45,570 shares of the medical equipment provider’s stock valued at $4,048,000 after purchasing an additional 922 shares in the last quarter. Chicago Partners Investment Group LLC boosted its position in shares of Zimmer Biomet by 18.1% in the third quarter. Chicago Partners Investment Group LLC now owns 10,439 shares of the medical equipment provider’s stock worth $1,029,000 after purchasing an additional 1,598 shares during the period. Covestor Ltd boosted its position in shares of Zimmer Biomet by 23.4% in the third quarter. Covestor Ltd now owns 1,081 shares of the medical equipment provider’s stock worth $96,000 after purchasing an additional 205 shares during the period. Finally, Trace Wealth Advisors LLC purchased a new stake in shares of Zimmer Biomet in the third quarter worth $204,000. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.